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Abstract
When CdSe/ZnS-polyethyleneimine (PEI) quantum dots (QDs) are microencapsulated in polymeric microcapsules, human
fibroblasts are protected from acute cytotoxic effects. Differences in cellular morphology, uptake, and viability were
assessed after treatment with either microencapsulated or unencapsulated dots. Specifically, QDs contained in
microcapsules terminated with polyethylene glycol (PEG) mitigate contact with and uptake by cells, thus providing a
tool to retain particle luminescence for applications such as extracellular sensing and imaging. The microcapsule serves as
the ‘‘first line of defense’’ for containing the QDs. This enables the individual QD coating to be designed primarily to
enhance the function of the biosensor.
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Introduction
Nanoscale materials are promising contenders for diagnostics,
therapeutics, and imaging agents due to their size, functionality,
and unique optical properties. Many of the proposed biomedical
applications for nanomaterials revolve around their employment
as targeted drug delivery vehicles in the circulatory system [1,2].
Another potential biomedical application of nanomaterials
includes their incorporation into medical implants, such as devices
placed in the subcutaneous tissue or even as functional elements of
‘‘smart’’ tattoo-like biosensors [3,4,5]. Such concepts require
engineered structures and materials with the desired function (e.g.,
optical sensing) within a fully biocompatible and/or biodegradable
platform [5]. As an example, many biosensors require mobility of
sensing reagents—the sensors/reagents must be able to, allowing
them to freely associate and dissociate, while being physically
constrained to enable continuous use in one location [5,6].
Inorganic nanoparticles offer unique properties that enable
innovative biosensing techniques. However, it is difficult to
localize the nanoparticles for long periods of time. Additionally,
the prospective use of nano-enabled biosensors for such in vivo
applications has raised concerns regarding the possible localized
and systemic toxicological effects in humans. Mechanistic analyses
of these effects in humans are needed when assessing the risks due
to the use of nanomaterials in medicine and biological imaging.
QDs with a cadmium selenide core (CdSe) and a zinc sulfide
(ZnS) shell remain the most studied, produced, and proposed
luminescent nanomaterial. Offering significant advantages for
energy transfer-based biosensors, QDs are photobleaching resis-
tant, have high quantum yield, and possess broad absorption/
narrow emission bands that are size tunable [17]. However, since
CdSe/ZnS QDs have been shown to enter living cells
[7,8,9,10,11,12], their toxicological characterization and mitiga-
tion is extremely relevant to nanobiotechnology. It has been shown
that the addition of a ZnS outer shell can minimize damage to the
cell [13]; however, the potential for substantial damage from
leaching cadmium, selenium, and/or excess zinc still exists
[14,15]. In addition, because QDs are intrinsically redox-active,
a portion of their toxic potential may also arise from such native
properties without regard to their composition, surface properties,
or cellular internalization potential. Quantum dots can transfer
absorbed optical energy to adjacent oxygen molecules, thus
spontaneously generating reactive oxygen species (ROS) such as
hydroxyl radical (
NOH), superoxide (O
22), and singlet oxygen (
1O2)
[16,17,18]. Further modification of the QD surface with silanes
[19], oligomeric phosphines [20], phospholipids [21], and
amphiphilic triblock copolymers [22] has been demonstrated as
an effective means to further mitigate toxicity by protecting the
QD surface from deterioration in biological media. However,
these capping agents increase overall QD size enough to preclude
efficient energy transfer to an acceptor [23]. Therefore, although
these bulky capping agents protect the QD from degradation,
biosensing schemes requiring intimate contact between QDs and
analytes/reagents (e.g., transduction via energy transfer) can incur
a loss in biosensor functionality.
As an alternative to protecting individual QDs, microencapsu-
lation provides a means to modulate interfacial interactions
between the cells and QDs without the need to deposit bulky
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e22079surface coatings on the QDs. Our work is separate from a large
body of work focused on encapsulating individual QDs, as we are
microencapsulating an ensemble of QDs (2.05e10) within each
polyelectrolyte microcapsule (2.05e10 QDs/microcapsule). It is
also noteworthy that the QDs used in this study are microencap-
sulated within the hollow interior (i.e., void) volume of the
polyelectrolyte microcapsule, which should be distinguished from
QD entrapment within the polyelectrolyte film itself [24] and
results in an interaction among the QDs, the solvent, and other
molecules that permeate the film. Although the two seem similar
superficially, important differences exist with respect to interac-
tions with surroundings and apparently toxicity, as evidenced by
our data.
Microcapsules and nanoparticle surface coatings can function as
protective layers to prevent or inhibit erosion, oxidation, and
leaching of core components; however, the leaching of core
components is a central challenge for the microencapsulation field
[25]. Numerous studies have shown that microcapsules synthe-
sized via the layer-by-layer (LbL) process inhibit the release of core
components and show promise for the development of new types
of nano-enabled biosensors [25,26,27]. Even one of the smallest
enzymes, trypsin (Mw=23.3 kDa; corresponding to an average
diameter of ,1–3 nm) does not leach from an LbL microcapsule
[28]. The PEI-coated QD materials (termed CdSe/ZnS-PEI) used
in this study are ,15 nm in all dimensions and are thus well
contained within the microcapsule (Figure 1). However, it is
important to note that the permeability of the microcapsules to
ions, small molecules, and even macromolecules can be tailored in
a number of ways, including modulation of the pH (during and
post-construction), ionic strength (during and post-construction),
solvent (during and post-construction), polymer composition, and
shell thickness (Antipov and Sukhorukov, 2004). Therefore, given
a sufficiently large disparity in molecular weight/size between the
analyte and the QD (or other assay components), a number of
strategies can be employed to entrap the sensing assay, while
maintaining permeability of ions and small molecules (e.g., the
analyte). Again, because the polyelectrolyte microcapsules are
hollow, the QDs retain their responsiveness to the environment.
Therefore, the purpose of this study was to examine the protective
effects of additional surface constructs, namely polymer micro-
capsules, in comparison with the toxicological effects of free CdSe/
ZnS-PEI QDs.
To more thoroughly mitigate the potential cellular toxicity
caused by reported dissociated metal ions [29] or ROS generation
from the QDs, we set out to microencapsulate CdSe/ZnS-PEI in
an effort to nullify the adverse effects of free QDs on cellular
morphology and metabolism, cytotoxicity, and apoptotic or
necrotic response (Figure 2). Specific to the case of implantable
biosensors under epidermal layers of skin, we have developed a
model that investigates the potential cytotoxicity, uptake, and
apoptotic response of QD-loaded microcapsules (QDMC). Hu-
man dermal fibroblasts (HDF), the cells that compose the majority
of the viable dermal layer, were exposed to CdSe/ZnS-PEI QDs
microencapsulated within PEG-terminated microcapsules com-
prised of poly(styrene sulfonate) (PSS) and poly(allylamine
hydrochloride) (PAH). The near-neutral surface charge of PEG-
terminated microcapsules results in minimized contact with cells,
providing an excellent biomedical tool, while retaining desirable
QD qualities. However, it is important to note that microencap-
sulating other types of nanoparticles is not only possible, but
potentially advantageous. For example, noble metal nanoparticles
that possess antioxidative effects (e.g., reactive oxygen species
scavengers) might benefit from microencapsulation to prevent
cellular internalization, while simultaneously preserving surface-
Figure 1. Quantum dot-loaded microcapsule characterization. (A) Schematic representation of the formation of QD-loaded microcapsules. (B)
Histogram of the size distribution of QDMCs. (C) Brightfield and (D) fluorescence images of the QDMCs, showing that the microcapsules are
monodisperse and contain QDs (ex/em 380/545).
doi:10.1371/journal.pone.0022079.g001
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the controlled release of a drug from polymeric nanoparticles,
wherein the drug to be delivered acts on cell surface receptors and
must be delivered extracellularly (e.g., vascular endothelial growth
factor).
Materials and Methods
Core/shell (CdSe/ZnS) QDs were synthesized in a coordinating
solvent tri-n-octylphosphine oxide (TOPO, 99%, Aldrich) in
accordance with previously published procedures [30]. The
synthesis was performed in a single mode CEM DiscoverH
microwave reactor operating at 300 W, 2.45 GHz. Cadmium
oxide (CdO, 99.99%, Alfa Aesar, 0.0514 g, 0.4 mM) along with
tetradecylphosphonic acid (TDPA,98%, Alfa Aesar, 0.2232 g,
0.8 mM) and TOPO (3.7768, 9 mM) were heated with continuous
stirring in a 125 mL glass flask. The mixture was heated to
approximately 300uC under argon (Ar) flow for 15 min. A
selenium stock solution (0.0411 g, 0.5 mM, Aldrich, 99%)
dissolved in 2.4 mL (2 g) of tri-n-octylphosphine (TOP, 99%,
Aldrich) TOP) was injected at 270uC and QDs were allowed to
grow for 150 s. A ZnS shell was grown on the CdSe cores by
injecting a mixture of Zn and S precursors: 1.6 mL (12 mM)
dimethylzinc (DMZ-1M in heptane, Aldrich), 0.42 mL (2 mM)
hexamethyldisilathiane (HMDS, Aldrich), and 6.3 mL (14 mM)
TOP. The reaction mixture was heated for 30 min at 200uC. The
quantum yield of the QDs increased on annealing the particles at a
temperature of ,100uC for a period of two hours.
The QDs were surface modified with high molecular weight
branched PEI (b-PEI) (Aldrich, MW 25,000) using similarly
reported procedures [31]. Briefly, a 10 mg/mL solution of b-PEI
in chloroform was mixed with an equal volume of 4–5 mM QDs.
The mixture was tumbled overnight at room temperature. QDs
were precipitated from the mixture by addition of excess
cyclohexane (Sigma-Aldrich, .99%) and suspended in deionized
water. Excess PEI was extracted from the aqueous QD solution by
addition of fresh chloroform, which phase-separated from water.
The zeta potential of the PEI coated QDs was measured at
approximately +29.766.2 mV by a Zetasizer Nano ZS (Malvern
Corp, Worcestershire, UK). The quantum yield of PEI coated
QDs as produced is estimated to be 11.1%.
To microencapsulate the QDs in microcapsules (Figure 1), QDs
were first entrapped in CaCO3 microparticles using a modification
of Petrov’s protocol [32]. Briefly, 2.4 mL of a 2.17 mM PEI-coated
QD solution was added to 7.6 mL of a Na2CO3 solution
containing 40 mg of PSS (Mw=70 kDa) for a final Na2CO3
concentration of 0.2 M. While stirring the Na2CO3 solution,
10 mL of a 0.2 M CaCl2 solution was quickly added. After stirring
for 30 s, the resulting particle suspension was centrifuged at 2500 g
Figure 2. Experimental design. Flowchart of the protocol used for testing the cellular response (cytotoxicity and morphology) of human dermal
fibroblasts (HDF) to free quantum dots (QD) and quantum dot loaded microcapsules (QDMC). Cultured cells were exposed to either QD or QDMC for
all experiments. CdCl2 was used in some experiments as a positive control. Cytotoxicity, including % dead, metabolism, and apoptosis, were
determined over a dose-response, while cellular morphology and uptake were determined over a time course.
doi:10.1371/journal.pone.0022079.g002
Table 1. QD and QDMC characterization table.
Property QD QDMC
Size in water 14–16 nm 3–5 mm
Surface charge +29.766.2 mV near neutral*
Interior volume - 14.14–65.45 mm
3
Calculated surface area ,706 nm
2 28.27–78.54 mm
2
No. of QDs/microcapsule - 2.05e10
No. of Cd
+2 ions/system 265.8 5.46e12
Excitation/Emission 380/545 nm 380/545 nm
*As measured on CaCO3 microparticles coated with (PSS/PAH)10/(PSS/PLL-g-
PEG) nanofilms.
doi:10.1371/journal.pone.0022079.t001
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the precipitate was rinsed three times with deionized water and
imaged using an inverted epifluorescence microscope (Nikon
Eclipse TE2000-U) with a 406objective (Nikon Plan Fluor, 0.75),
1.56secondary magnification, and a color digital camera (Nikon
DS-Fi1). Particle size measurements were performed using an
Elzone II Particle Size Analyzer equipped with a 30 mm orifice
tube (Micromeritics, Norcross, GA). Particle diameter was
validated via optical microscopy. Zeta potential measurements,
as an indicator of microcapsule surface charge, were performed
using a Zetasizer Nano ZS (Malvern Corp, Worcestershire, UK).
Encapsulation efficiency was estimated by measuring the fluores-
cence intensity of the QDMC solution and dividing by the sum of
the fluorescence intensities of the QDMC solution and the
supernatant solution recovered from the CaCO3 microparticle
precipitation, which contained unencapsulated QDs. Due to the
high scattering of the samples, a PC1 photon counting
spectrofluorometer (ISS, Champaign, IL) was modified using a
bifurcated fiber optic bundle to collect fluorescence using 180u
collection geometry. Empty CaCO3 microcapsules (containing no
QDs) were prepared using the aforementioned protocol, with the
exception that 2.4 mL of deionized water was substituted for the
PEI-coated QD solution.
Nanofilms were deposited on the CaCO3 template using the
LbL method, in which substrates are immersed in polyelectrolyte
solutions of alternating charge [33,34,35]. The first ten bilayers
were comprised of polyelectrolytes PSS and PAH (Mw=52 kDa).
The surface charge of CaCO3 microparticles at or below pH 8 is
positive, so anionic PSS was the first polyelectrolyte deposited,
followed by cationic PAH [36]. Deposition of each polyelectrolyte
Figure 3. Differential cytotoxicity. Cytotoxicity was measured at A) 12 hrs, B) 24 hrs, and C) 48 hrs via fluorescence intensity of reduced resazurin.
HDF cells at all time points were either exposed to 0.05–50 nM QDs or microencapsulated QDMCs, 20 or 120 mM cadmium chloride positive control,
or unexposed. * p-val,0.05, ** p-val,0.001. Note: the QDMC concentrations refer to the total concentration of QDs contained in the microcapsules.
doi:10.1371/journal.pone.0022079.g003
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mL polyelectrolyte solution containing 0.2 M NaCl. Lastly, the
particles were coated with a terminal bilayer comprised of PSS and
poly-L-lysine(100)-g[4.5]-polyethylene glycol(114) (PLL-g-PEG,
Alamanda Polymers, Mw=129 kDa), yielding CaCO3 micropar-
ticles coated with a (PSS/PAH)10/(PSS/PLL-g-PEG) nanofilm.
Dissolution of the CaCO3 template was accomplished via a mild
treatment with 0.1 M ethylenediaminetetraacetic acid (EDTA)
adjusted to pH 7.6; complete core dissolution was visually
confirmed using phase microscopy.
For viability and internalization experiments, HDF cells
(ATCC, Manassas, VA) were cultured in Dulbecco’s Modified
Eagle’s Medium (DMEM, Gibco, Austria), which was supple-
mented with 10% FBS and an antibiotic cocktail consisting of
penicillin, streptomycin, and amphotericin (Sigma-Aldrich, St.
Louis, MO). Incubation took place at 37uC with humidity and 5%
CO2.
Live cells were cultured as above and treated with 50 pM QD
and QDMC for 30 min, 4 hrs, 12 hrs, 24 hrs, and 48 hrs to
determine the manner and extent of QD uptake into the
fibroblasts. An undosed control was also included for comparison.
Then, 0.25 mL stock solution Syto 63 (Invitrogen, Carlsbad, CA)
was directly added to 1 mL of media in the borosilicate, dual-well
chamber slides (Lab-Tek, Nagle Nunc Intl., Rochester, NY) for a
30 min incubation at 37uC. A Zeiss 510 Meta confocal microscope
was utilized at 406(1.3 NA, oil immersion) to image the treated
and stained live cells. A 488 nm Ar ion and a 633 nm He-Ne laser
were employed to excite the QDs and stain, respectively. Zeiss
LSM 510 Software was used to acquire the images.
Cell populations (n=4) were then seeded in 24 well plates,
allowed to grow to 80% confluency, and dosed with 0.05–50 nM
concentration range for both the QD and QDMC or left undosed
as a negative control. A 20 and 120 mM CdCl2 solution was
utilized as a positive indicator for absence of fluorescent probe
metabolism. The dosed media was aspirated after 12, 24, or 48 hr.
The cells were washed with PBS and phenol red-free DMEM
media was added. Resazurin dye (10% v/v, Sigma Aldrich, St.
Louis, MO) was added and the cells were incubated for an
additional 3 hr. Fluorescence intensity was obtained by exciting at
560 nm and recording emission at 590 nm. Fluorescence
compatibility was measured prior to assay (Figure S2). QD and
QDMC toxicity to cells was measured in terms of percent healthy
cells via microscopy.
Results
The average microparticle diameter was determined to be
5.24 mm as measured with a particle size analyzer, with a standard
deviation of 1.25 mm (95% confidence interval: 5.165–5.317 mm)
(Table 1 and Figure 1B). This diameter was also observed via
optical microscopy. The encapsulation efficiency was determined
to be ,30.57%, resulting in about 9,000,000 QDs/microcapsule.
At this encapsulated concentration, the volume occupied by the
microencapsulated QDs is ,0.1% of the total microcapsule
interior volume. Based on the diameter of the microcapsule, the
average surface area would be 7.854610
211 m
2 (i.e., 78.54 mm
2).
Figure 1 depicts the process used to form the QDMC.
Morphology of the microcapsules was determined with microsco-
py. Following core dissolution, brightfield and fluorescence images
of the resulting microcapsules were acquired (Figure 1 C&D). The
brightfield image reveals a spherical morphology, and the
fluorescence image confirms successful QD microencapsulation.
Both the micrographs and the histogram show that the QDMC
sample contains monodisperse microcapsules. In addition, QDs do
not show evidence of self-quenching (i.e., red-shift of emission
peak) once microencapsulated, as shown by the fluorescence
emission spectra in Figure S3.
Cellular viability was measured in two independent studies.
First, viable cells were counted using brightfield microscopy (data
not shown). Second, changes in metabolic activity were measured
using the conversion of resazurin to resorufin (Figure 3). In both
studies, HDF cells were exposed to QDs, QDMCs, and CdCl2
Figure 4. QD association and cellular morphology. (A) QD
accumulation in HDF mitochondria (Confocal, 606, Zeiss). (B) The
number of QD aggregates accumulating in HDF increases over time.
Fluorescence images of cells dosed with QDs at the (C) 12 hr and (D)
48 hr time points. Images of cells dosed with QDMCs (at an equivalent
amount of Cd
+2 ions relative to QDs) at the (E) 12 hr and (F) 48 hr time
points. Microcapsules are resting on top of cells, but do not enter cells.
Cells dosed with an equivalent Cd atom concentration of the QD-
loaded microcapsules displayed no evidence of particle uptake and
remained viable with no sign of deterioration through the 48 hr time
point.
doi:10.1371/journal.pone.0022079.g004
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each concentration was kept constant between the QD and
QDMC samples; e.g., 5 nM QDMC refers to enough MCs to
provide a total QD concentration of 5 nM. All responses were
compared to those of undosed cells. Results indicated a strong
dose- and time-dependent response relationship present in QD
and CdCl2-treated cells, but no significant changes in metabolic
activity were found by 48 hr in QDMC-treated cells. Cells
exposed to empty microcapsules were also examined for changes
in viability and metabolic activity and no significant changes were
found. These findings corroborate the cellular morphology
microscopy data (Figure 4).
It is important to note that QDs are similarly toxic at much lower
concentrations than the cadmium chloride positive control. This is
not surprising sincethere arefactors other than chemical composition
(e.g. surface charge, particle size, ROS generation potential)that must
be considered when evaluating nanoparticle cytotoxicity. For
example, it has been shown that cadmium-containing QDs are
more toxic to bacteria than an equivalent cadmium concentration of
cadmium salt due to higher ROS generation, damaged cell
membranes, and the presence of Se
0 and dissolved cadmium [37].
Figure 4 and Figure S1 show that the free QDs visibly disrupted
the cellular morphology, which became apparent after the 12 hr
time point and progressed throughout the remainder of the
experiment. Cells dosed with an equivalent Cd atom concentra-
tion of the QD-loaded microcapsules displayed no evidence of
particle uptake and remained viable with no sign of deterioration
through the 48 hr time point.
Discussion
Due to the recent surge of nanoparticle development for
imaging and therapeutic applications, there is reason to evaluate
toxicity of nanomaterials. Some studies suggest nanoparticles do
affect biological systems at the cellular, subcellular, and protein
levels [38,39,40]. Other works indicate that nanoparticles are
cleared from circulation by macrophages depending on particle
composition, size, charge, surrounding pH, dose, or route of
exposure [41,42,43,44]. Nevertheless, there are concerns that Cd-
containing QDs are toxic to both cell cultures and live animals
because they contain a toxic heavy metal. Are there engineering
solutions that can mitigate the nanoparticle toxicity while
maintaining functionality?
Previous studies have shown that the endocytosis of nanoparticles
in acidic endosomes degrade nanomaterials and cause leaching of
metals, thus producing stress, triggering apoptotic response, and
eventual death [45]. We propose that the observed death could be
mitigated by controlling uptake via microencapsulation and altering
microcapsule outer surface charge. These mitigations can improve
the biocompatibility of QDs by decreasing internalization. Data
from the literature has indicated that particles that remain in the
extracellular matrix are typically less toxic to cells than particles that
have breached the cytoplasmic membrane [46,47,48]. Research
presented in this paper suggests that QDMC biocompatibility is due
to lack of cellular uptake and is evidenced by normal mitochondrial
function. Therefore, as new nanomaterials (including microencap-
sulated systems or composited materials) that possess useful physical
and chemical properties are developed, understanding the propen-
sity for cellular uptake and subsequent adverse cellular effects is vital.
Cellular uptake is an additional parameter to be considered in
the design and evaluation of biocompatible nanoparticles for
biological applications. This data provides strong evidence that
specific microencapsulation of CdSe/ZnS particles imparts
substantial protection. The most common capping strategies are
known to decrease toxicity, but they also often decrease
functionality by increasing the size of the QDs. We have shown
here that by microencapsulation of the nanoparticle, toxicity is
decreased, while luminescence – a precursor for functionality –
remains uncompromised.
Supporting Information
Figure S1 Cellular morphology over time. Micrographs B
through F show the cellular morphology of HDFs exposed to QDs
over a 30 minute to 48 hour time course study. As exposure time
increases, the cells exhibit compromised cytoplasmic membrane.
Micrographs H through L show the cellular morphology of HDFs
exposed to QDMC over a 30 minute to 48 hour time course
study. Cells remain intact and healthy over the course of the 2-day
study. Z-stack images indicate that microcapsules do not enter
cells.
(TIF)
Figure S2 Fluorescence compatibility of QDs and
resorufin in resazurin assay. Fluorescence spectral emission
wavelengths of QDs and resorufin, product of resazurin, when
excited at 560 nm. Resazurin assay data was collected at 590 nm.
(TIF)
Figure S3 Unencapsulated QDs and microencapsulated
QDs fluorescence emission spectra (after normalization
to the peak intensity). Because the spectra are identicalshow
no spectral shift to longer wavelength upon microencapsulation,
the quantum dotQDs are not self-quenching within the micro-
capsules after microencapsulation. The spectra are essentially the
same, and there is no evidence of the characteristic red-shift that is
associated with self-quenching.
(TIF)
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